Novocure (NVCR) Misses Q2 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
NovoCure Ltd. (NVCR) PT Raised to $44 at Mizuho Securities
July 27, 2018 8:44 AM EDTMizuho Securities raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $44.00 (from $32.00) while maintaining a Buy rating.
Analyst Difei Yang commented, "NovoCure reported 2Q18 results yesterday. Net revenue of $61.5 mil beat FactSet consensus of $59.5 mil while EPS of $(0.17) was slightly below consensus of... More
Deutsche Bank Downgrades NovoCure Ltd. (NVCR) to Hold
July 25, 2018 4:06 PM EDTDeutsche Bank downgraded NovoCure Ltd. (NASDAQ: NVCR) from Buy to Hold with a price target of $31.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $36.30 yesterday.
... More